MedTrace Logo

Study of Herbal Formula Corresponding to Syndrome in Treating Post Percutaneous Coronary Intervention (PCI) Patients With Coronary Heart Disease (CHD)

NCT00817024 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2012-06-01

No results posted yet for this study

Summary

We conduct this clinical trial to determine the effects of Xuefu Zhuyu capsule (based on TCM "Zheng Hou" theory) in helping recovery from coronary heart disease(CHD)after PCI and find out whether this kind of effecacy is much better within patients administered with TCM syndrome-based individualized medication.

Conditions

Interventions

DRUG

Xuefu Zhuyu Capsules Plus Placebo of Sheng Mai Capsules,

3# XFZY capsules plus 3# placebo of SM capsules, po, Tid, for 4 weeks

DRUG

Sheng Mai Capsules Plus Placebo of Xuefu Zhuyu Capsules

3# SM capsules plus 3# placebo of XFZY capsules, po, Tid, for 4 weeks

DRUG

Placebo of Xuefu Zhuyu Capsules Plus Placebo of Sheng Mai Capsules

3# Placebo of XFZY capsules plus 3# placebo of SM capsules, po, Tid, for 4 weeks

Sponsors & Collaborators

  • Beijing Anzhen Hospital

    collaborator OTHER

  • Guang'anmen Hospital of China Academy of Chinese Medical Sciences

    lead OTHER

Principal Investigators

  • Jie Wang, M.D. · China Academy of Chinese Medical Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2009-03-31
Completion
2009-03-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00817024 on ClinicalTrials.gov